Comparative Analysis of Digital Transcriptomics Between Pre- and Post-Treatment Samples of Patients with Locally Advanced Cervical Cancer: A Preliminary Study

Overview

Journal Curr Issues Mol Biol

Publisher MDPI

Specialty Molecular Biology

Date 2024 Nov 26

PMID 39590310

Authors

Sunhwa Baek

Fabian Dominik Mairinger

Sabrina Borchert

Yue Zhao

Dominik Ratiu

Peter Konrad Mallmann

Henryk Pilch

Ka-Won Noh

Affiliations

Soon will be listed here.

Abstract

Cervical cancer remains a leading cause of cancer-related deaths in women worldwide, with limited treatment options for advanced stages and therapy-resistant cases. Despite advances in treatment, the variability in the patient response to standard therapies underscores the need for molecular biomarkers to guide personalized treatment strategies. This study aimed to explore the transcriptomic changes associated with the therapeutic response in locally advanced cervical cancer, focusing on 770 immune-related genes. We employed a digital multiplexed gene expression analysis, comparing gene expression profiles between matching pre- and post-treatment samples. The results revealed the significant upregulation of C7 and EGR2 in the post-treatment samples, suggesting that enhanced immune activity is a key factor in therapeutic success. Conversely, IL17RB, S100A7, and SAA1 were upregulated in the pre-treatment samples, potentially indicating resistance mechanisms. Pathway enrichment analysis highlighted that the immune response and apoptosis pathways are crucial to post-treatment changes. These findings suggest that C7, EGR2, and IL17RB may serve as biomarkers for predicting therapeutic outcomes and could inform the development of more effective, individualized treatment strategies for cervical cancer. This study provides new insights into the molecular mechanisms underlying treatment response and resistance.

Citing Articles

Introduction to Special Issue: Genomic Analysis of Common Disease.

Wilson G Curr Issues Mol Biol. 2025; 47(2).

PMID: 39996832 PMC: 11854786. DOI: 10.3390/cimb47020112.

References

George Onyango C, Ogonda L, Guyah B, Shiluli C, Ganda G, Orango O . Novel biomarkers with promising benefits for diagnosis of cervical neoplasia: a systematic review. Infect Agent Cancer. 2020; 15(1):68. PMC: 7670699. DOI: 10.1186/s13027-020-00335-2. View

Gupta S, Maheshwari A, Parab P, Mahantshetty U, Hawaldar R, Sastri Chopra S . Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients With Stage IB2, IIA, or IIB Squamous Cervical Cancer: A Randomized Controlled Trial. J Clin Oncol. 2018; 36(16):1548-1555. DOI: 10.1200/JCO.2017.75.9985. View

Mereu L, Pecorino B, Ferrara M, Tomaselli V, Scibilia G, Scollo P . Neoadjuvant Chemotherapy plus Radical Surgery in Locally Advanced Cervical Cancer: Retrospective Single-Center Study. Cancers (Basel). 2023; 15(21). PMC: 10648104. DOI: 10.3390/cancers15215207. View

Qiu L, Feng H, Yu H, Li M, You Y, Zhu S . Characterization of the Genomic Landscape in Cervical Cancer by Next Generation Sequencing. Genes (Basel). 2022; 13(2). PMC: 8871541. DOI: 10.3390/genes13020287. View

Bie Q, Song H, Chen X, Yang X, Shi S, Zhang L . IL-17B/IL-17RB signaling cascade contributes to self-renewal and tumorigenesis of cancer stem cells by regulating Beclin-1 ubiquitination. Oncogene. 2021; 40(12):2200-2216. PMC: 7994204. DOI: 10.1038/s41388-021-01699-4. View

Unoki M, Nakamura Y . EGR2 induces apoptosis in various cancer cell lines by direct transactivation of BNIP3L and BAK. Oncogene. 2003; 22(14):2172-85. DOI: 10.1038/sj.onc.1206222. View

Laprevotte E, Cochaud S, Du Manoir S, Lapierre M, Dejou C, Philippe M . The IL-17B-IL-17 receptor B pathway promotes resistance to paclitaxel in breast tumors through activation of the ERK1/2 pathway. Oncotarget. 2018; 8(69):113360-113372. PMC: 5768333. DOI: 10.18632/oncotarget.23008. View

Tewari K, Sill M, Long 3rd H, Penson R, Huang H, Ramondetta L . Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014; 370(8):734-43. PMC: 4010094. DOI: 10.1056/NEJMoa1309748. View

Chen Z, Yan X, Du G, Tuoheti K, Bai X, Wu H . Complement C7 (C7), a Potential Tumor Suppressor, Is an Immune-Related Prognostic Biomarker in Prostate Cancer (PC). Front Oncol. 2020; 10:1532. PMC: 7477933. DOI: 10.3389/fonc.2020.01532. View

10.

Lee H, Kim M, Park K, Bae Y, Yun J, Park J . Serum amyloid A stimulates matrix-metalloproteinase-9 upregulation via formyl peptide receptor like-1-mediated signaling in human monocytic cells. Biochem Biophys Res Commun. 2005; 330(3):989-98. DOI: 10.1016/j.bbrc.2005.03.069. View

11.

Urieli-Shoval S, Linke R, Matzner Y . Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr Opin Hematol. 1999; 7(1):64-9. DOI: 10.1097/00062752-200001000-00012. View

12.

Ying L, Zhang F, Pan X, Chen K, Zhang N, Jin J . Complement component 7 (C7), a potential tumor suppressor, is correlated with tumor progression and prognosis. Oncotarget. 2016; 7(52):86536-86546. PMC: 5349933. DOI: 10.18632/oncotarget.13294. View

13.

Zubizarreta E, Fidarova E, Healy B, Rosenblatt E . Need for radiotherapy in low and middle income countries – the silent crisis continues. Clin Oncol (R Coll Radiol). 2014; 27(2):107-14. DOI: 10.1016/j.clon.2014.10.006. View

14.

Wang S, Hu W, Xie Y, Wu H, Jia Z, Zhang Z . Functional genetic variants in complement component 7 confer susceptibility to gastric cancer. PeerJ. 2022; 10:e12816. PMC: 8781313. DOI: 10.7717/peerj.12816. View

15.

Mitra T, Elangovan S . Cervical cancer development, chemoresistance, and therapy: a snapshot of involvement of microRNA. Mol Cell Biochem. 2021; 476(12):4363-4385. DOI: 10.1007/s11010-021-04249-4. View

16.

Harris J, Bishop K, Phillips N, Mordes J, Greiner D, Rossini A . Early growth response gene-2, a zinc-finger transcription factor, is required for full induction of clonal anergy in CD4+ T cells. J Immunol. 2004; 173(12):7331-8. DOI: 10.4049/jimmunol.173.12.7331. View

17.

Liao Y, Wang J, Jaehnig E, Shi Z, Zhang B . WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs. Nucleic Acids Res. 2019; 47(W1):W199-W205. PMC: 6602449. DOI: 10.1093/nar/gkz401. View

18.

Da Silva D, Enserro D, Mayadev J, Skeate J, Matsuo K, Pham H . Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929). Clin Cancer Res. 2020; 26(21):5621-5630. PMC: 7642021. DOI: 10.1158/1078-0432.CCR-20-0776. View

19.

Wu H, Hwang-Verslues W, Lee W, Huang C, Wei P, Chen C . Targeting IL-17B-IL-17RB signaling with an anti-IL-17RB antibody blocks pancreatic cancer metastasis by silencing multiple chemokines. J Exp Med. 2015; 212(3):333-49. PMC: 4354366. DOI: 10.1084/jem.20141702. View

20.

de Bruijn I, Kundra R, Mastrogiacomo B, Tran T, Sikina L, Mazor T . Analysis and Visualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal. Cancer Res. 2023; 83(23):3861-3867. PMC: 10690089. DOI: 10.1158/0008-5472.CAN-23-0816. View